Abstract
Laboratory and clinical studies of pazufloxacin (PZFX), a newly developed synthetic antibacterial agent of quinolone derivative, were performed.
MICs of this and 8 other control drugs against 340 strains of 14 species of bacteria were determined. Among gram-positive bacteria, MIC90 of this drug against methicillin-susceptible Staphylococcus aureus, methicillin-resistant S. aureus and Staphylococcus epidermidis were 0.20, 12.5, 0.39 μg/ml respectively, and the antibacterial effect ranked next to that of tosufloxacin (TFLX). The antibacterial effect on other gram-positive bacteria was, however, slightly weaker than those of control drugs.
Against gram-negative bacteria, on the other hand, the antibacterial effect on Haemophilus influenzae and Escherichia coil, were excellent with MICs of ≤0.025 μg/ml. The antibacterial effect on other gramnegative bacteria was almost equal to that of TFLX. Against Pseudomonas aeruginosa which showed MICs more than 6.25 and 25 μg/ml respectively with imipenem and gentamicin, the antibacterial effect was superior to those of other control drugs with MIC90 of 3.13 μg/ml.
In the clinical study, 11 cases of respiratory infection and 2 cases of urinary infection were studied. The clinical effect was excellent in 3 cases and good in 10 cases with the effective rate of 100%. All bacteria detected in 3 cases were eradicated. As for side effects, headache and nausea were noted in 1 case. In addition, increased GOT, GPT, ALP, γ-GTP, and LAP were observed in 1 case.
